Northern Right Capital Management adds PharmAthene (PIP) to its portfolio

PharmAthene (PIP) : Northern Right Capital Management added new position in PharmAthene during the most recent quarter end. The investment management firm now holds 460,044 shares of PharmAthene which is valued at $1,186,914 , the company said in a statement filed on Aug 15, 2016 with the SEC.PharmAthene makes up approximately 1.55% of Northern Right Capital Management’s portfolio.

Other Hedge Funds, Including , Guggenheim Capital boosted its stake in PIP in the latest quarter, The investment management firm added 1,966 additional shares and now holds a total of 15,408 shares of PharmAthene which is valued at $39,753. Renaissance Technologies added PIP to its portfolio by purchasing 149,200 company shares during the most recent quarter which is valued at $384,936.Geode Capital Management boosted its stake in PIP in the latest quarter, The investment management firm added 75,842 additional shares and now holds a total of 375,376 shares of PharmAthene which is valued at $968,470. Tiaa Cref Investment Management added PIP to its portfolio by purchasing 201,249 company shares during the most recent quarter which is valued at $519,222.Tfs Capital boosted its stake in PIP in the latest quarter, The investment management firm added 193,629 additional shares and now holds a total of 211,370 shares of PharmAthene which is valued at $545,335. PharmAthene makes up approx 0.09% of Tfs Capital’s portfolio.

PharmAthene closed down -0.01 points or -0.38% at $2.59 with 81,040 shares getting traded on Thursday. Post opening the session at $2.6, the shares hit an intraday low of $2.57 and an intraday high of $2.6 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

Pharmathene Inc. (Pharmathene) is a biodefense company. The Company is engaged in the development of medical counter measures against biological and chemical threats. The Company has several biodefense candidates in its portfolio: Anthrax vaccines including SparVax which is a second generation liquid recombinant protective antigen (rPA) anthrax vaccine and a lyophilized anthrax vaccine containing rPA; rBChE (recombinant butyrylcholinesterase) bioscavenger which is a medical counter measure for nerve agent poisoning by organophosphorous (OP) compounds including nerve gases and pesticides and Valortim which is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The Company develops Valortim in collaboration with Bristol-Myers Squibb (BMS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *